Skip to main content

Table 1 Patients’ characteristics by time to diagnosis of breast cancer recurrence

From: Factors that predict recurrence later than 5 years after initial treatment in operable breast cancer

   Time to recurrence Total (n = 300) p
   <5 years (n = 180) ≥5 years (n = 120)   
Mean age, years (SD)   48.45 (10.59) 49.17 (10.61) 300 0.562
Menopausal status Pre/peri-menopause 138 (76.6) 83 (69.1) 221 0.628
  Postmenopause 42 (23.4) 37 (30.9) 79  
T stage ≤2 cm 40 (22.2) 51 (42.5) 91 <0.001
  >2 cm 140 (77.8) 69 (57.5) 209  
N stage Node-negative 53 (29.4) 69 (56.6) 122 <0.001
  Node + 1-3 nodes 56 (31.1) 36 (30) 92  
Node + 4-9 nodes 39 (21.7) 12 (10) 51
Node+ ≥ 10 nodes 32 (17.8) 3 (2.5) 35
N stage Node-negative 53 (29.4) 69 (56.6) 121 <0.001
  Node-positive 127 (70.6) 51 (43.4) 179  
Grade (n = 262) 1 13 (7.6) 19 (20.6) 32 0.002
  2 103 (60.5) 56 (60.8) 159  
  3 54 (31.9) 17 (18.6) 71  
LVI (n = 262) Yes 108 (63.9) 43 (46.2) 151 0.006
  No 61 (36.1) 50 (53.8) 111  
ER Positive 101 (56.1) 104 (86.6) 205 0.001
  Negative 79 (43.9) 16 (13.4) 95  
PR Positive 76 (42.2) 95 (79.1) 171 0.001
  Negative 104 (57.8) 25 (20.9) 129  
HER2 Positive 60 (33.3) 5 (4.1) 65 0.001
  Negative 120 (66.7) 115 (95.9) 235  
Subtypes Luminal A/B/HER2 76 (42.2) 102 (85.0) 178 0.001
  Triple-negative 44 (24.4) 13 (10.8) 57  
  HER2 35 (19.4) 2 (1.6) 37  
  ER+ or PR+ and HER2+ 25 (14.0) 3 (2.6) 28  
Surgery (n = 293) Mastectomy 163 (90.5) 106 (88.3) 269 0.31
Breast-conserving 12 (6.7) 12 (10) 24
Adjuvant systemic treatment None 8 (4.4) 4 (3.3) 12 0.001
Chemotherapy 81 (45.0) 20 (16.6) 101  
Endocrine therapy 17 (9.4) 35 (29.1) 52  
Chemo-endocrine 74 (41.2) 61 (51.0) 135  
Adjuvant RT Yes 108 (60.0) 47 (39.1) 155 0.073